Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2
Summary: Global deployment of an effective and safe vaccine is necessary to curtail the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we evaluated a Newcastle disease virus (NDV)-based vectored-vaccine in mice and hamsters for its i...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-09-01
|
| Series: | iScience |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589004221009093 |
| _version_ | 1818576760364597248 |
|---|---|
| author | Jun-Gyu Park Fatai S. Oladunni Mohammed A. Rohaim Jayde Whittingham-Dowd James Tollitt Matthew D.J. Hodges Nadin Fathallah Muhsref Bakri Assas Wafaa Alhazmi Abdullah Almilaibary Munir Iqbal Pengxiang Chang Renee Escalona Vinay Shivanna Jordi B. Torrelles John J. Worthington Lucy H. Jackson-Jones Luis Martinez-Sobrido Muhammad Munir |
| author_facet | Jun-Gyu Park Fatai S. Oladunni Mohammed A. Rohaim Jayde Whittingham-Dowd James Tollitt Matthew D.J. Hodges Nadin Fathallah Muhsref Bakri Assas Wafaa Alhazmi Abdullah Almilaibary Munir Iqbal Pengxiang Chang Renee Escalona Vinay Shivanna Jordi B. Torrelles John J. Worthington Lucy H. Jackson-Jones Luis Martinez-Sobrido Muhammad Munir |
| author_sort | Jun-Gyu Park |
| collection | DOAJ |
| description | Summary: Global deployment of an effective and safe vaccine is necessary to curtail the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we evaluated a Newcastle disease virus (NDV)-based vectored-vaccine in mice and hamsters for its immunogenicity, safety, and protective efficacy against SARS-CoV-2. Intranasal administration of recombinant (r)NDV-S vaccine expressing spike (S) protein of SARS-CoV-2 to mice induced high levels of SARS-CoV-2-specific neutralizing immunoglobulin A (IgA) and IgG2a antibodies and T-cell-mediated immunity. Hamsters immunized with two doses of vaccine showed complete protection from lung infection, inflammation, and pathological lesions following SARS-CoV-2 challenge. Importantly, administration of two doses of intranasal rNDV-S vaccine significantly reduced the SARS-CoV-2 shedding in nasal turbinate and lungs in hamsters. Collectively, intranasal vaccination has the potential to control infection at the site of inoculation, which should prevent both clinical disease and virus transmission to halt the spread of the COVID-19 pandemic. |
| first_indexed | 2024-12-16T06:19:08Z |
| format | Article |
| id | doaj.art-8242157c2dd5466785ee86b3db0c87ec |
| institution | Directory Open Access Journal |
| issn | 2589-0042 |
| language | English |
| last_indexed | 2024-12-16T06:19:08Z |
| publishDate | 2021-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | iScience |
| spelling | doaj.art-8242157c2dd5466785ee86b3db0c87ec2022-12-21T22:41:11ZengElsevieriScience2589-00422021-09-01249102941Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2Jun-Gyu Park0Fatai S. Oladunni1Mohammed A. Rohaim2Jayde Whittingham-Dowd3James Tollitt4Matthew D.J. Hodges5Nadin Fathallah6Muhsref Bakri Assas7Wafaa Alhazmi8Abdullah Almilaibary9Munir Iqbal10Pengxiang Chang11Renee Escalona12Vinay Shivanna13Jordi B. Torrelles14John J. Worthington15Lucy H. Jackson-Jones16Luis Martinez-Sobrido17Muhammad Munir18Texas Biomedical Research Institute, Host-Pathogen Interactions and Population Health Programs, San Antonio, TX 78227, USATexas Biomedical Research Institute, Host-Pathogen Interactions and Population Health Programs, San Antonio, TX 78227, USADivision of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster LA1 4YG, UK; Department of Virology, Faculty of Veterinary Medicine, Cairo University, Giza, 12211, EgyptDivision of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster LA1 4YG, UKDivision of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster LA1 4YG, UKDivision of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster LA1 4YG, UKDivision of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster LA1 4YG, UKFaculty of Applied Medical Sciences, Department of Medical Laboratory Technology, Immunology Group, King Abdul Aziz University, Jeddah 80200, Saudi ArabiaFaculty of Applied Medical Sciences, Department of Medical Laboratory Technology, Microbiology Group, King Abdul Aziz University, Jeddah 80200, Saudi ArabiaFaculty of Medicine, Al Baha University, Al Baha 77388, Saudi ArabiaThe Pirbright Institute, Woking GU24 0NF, UKThe Pirbright Institute, Woking GU24 0NF, UKTexas Biomedical Research Institute, Host-Pathogen Interactions and Population Health Programs, San Antonio, TX 78227, USATexas Biomedical Research Institute, Host-Pathogen Interactions and Population Health Programs, San Antonio, TX 78227, USATexas Biomedical Research Institute, Host-Pathogen Interactions and Population Health Programs, San Antonio, TX 78227, USADivision of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster LA1 4YG, UKDivision of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster LA1 4YG, UKTexas Biomedical Research Institute, Host-Pathogen Interactions and Population Health Programs, San Antonio, TX 78227, USADivision of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster LA1 4YG, UK; Corresponding authorSummary: Global deployment of an effective and safe vaccine is necessary to curtail the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we evaluated a Newcastle disease virus (NDV)-based vectored-vaccine in mice and hamsters for its immunogenicity, safety, and protective efficacy against SARS-CoV-2. Intranasal administration of recombinant (r)NDV-S vaccine expressing spike (S) protein of SARS-CoV-2 to mice induced high levels of SARS-CoV-2-specific neutralizing immunoglobulin A (IgA) and IgG2a antibodies and T-cell-mediated immunity. Hamsters immunized with two doses of vaccine showed complete protection from lung infection, inflammation, and pathological lesions following SARS-CoV-2 challenge. Importantly, administration of two doses of intranasal rNDV-S vaccine significantly reduced the SARS-CoV-2 shedding in nasal turbinate and lungs in hamsters. Collectively, intranasal vaccination has the potential to control infection at the site of inoculation, which should prevent both clinical disease and virus transmission to halt the spread of the COVID-19 pandemic.http://www.sciencedirect.com/science/article/pii/S2589004221009093immunologyvirology |
| spellingShingle | Jun-Gyu Park Fatai S. Oladunni Mohammed A. Rohaim Jayde Whittingham-Dowd James Tollitt Matthew D.J. Hodges Nadin Fathallah Muhsref Bakri Assas Wafaa Alhazmi Abdullah Almilaibary Munir Iqbal Pengxiang Chang Renee Escalona Vinay Shivanna Jordi B. Torrelles John J. Worthington Lucy H. Jackson-Jones Luis Martinez-Sobrido Muhammad Munir Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2 iScience immunology virology |
| title | Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2 |
| title_full | Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2 |
| title_fullStr | Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2 |
| title_full_unstemmed | Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2 |
| title_short | Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2 |
| title_sort | immunogenicity and protective efficacy of an intranasal live attenuated vaccine against sars cov 2 |
| topic | immunology virology |
| url | http://www.sciencedirect.com/science/article/pii/S2589004221009093 |
| work_keys_str_mv | AT jungyupark immunogenicityandprotectiveefficacyofanintranasalliveattenuatedvaccineagainstsarscov2 AT fataisoladunni immunogenicityandprotectiveefficacyofanintranasalliveattenuatedvaccineagainstsarscov2 AT mohammedarohaim immunogenicityandprotectiveefficacyofanintranasalliveattenuatedvaccineagainstsarscov2 AT jaydewhittinghamdowd immunogenicityandprotectiveefficacyofanintranasalliveattenuatedvaccineagainstsarscov2 AT jamestollitt immunogenicityandprotectiveefficacyofanintranasalliveattenuatedvaccineagainstsarscov2 AT matthewdjhodges immunogenicityandprotectiveefficacyofanintranasalliveattenuatedvaccineagainstsarscov2 AT nadinfathallah immunogenicityandprotectiveefficacyofanintranasalliveattenuatedvaccineagainstsarscov2 AT muhsrefbakriassas immunogenicityandprotectiveefficacyofanintranasalliveattenuatedvaccineagainstsarscov2 AT wafaaalhazmi immunogenicityandprotectiveefficacyofanintranasalliveattenuatedvaccineagainstsarscov2 AT abdullahalmilaibary immunogenicityandprotectiveefficacyofanintranasalliveattenuatedvaccineagainstsarscov2 AT muniriqbal immunogenicityandprotectiveefficacyofanintranasalliveattenuatedvaccineagainstsarscov2 AT pengxiangchang immunogenicityandprotectiveefficacyofanintranasalliveattenuatedvaccineagainstsarscov2 AT reneeescalona immunogenicityandprotectiveefficacyofanintranasalliveattenuatedvaccineagainstsarscov2 AT vinayshivanna immunogenicityandprotectiveefficacyofanintranasalliveattenuatedvaccineagainstsarscov2 AT jordibtorrelles immunogenicityandprotectiveefficacyofanintranasalliveattenuatedvaccineagainstsarscov2 AT johnjworthington immunogenicityandprotectiveefficacyofanintranasalliveattenuatedvaccineagainstsarscov2 AT lucyhjacksonjones immunogenicityandprotectiveefficacyofanintranasalliveattenuatedvaccineagainstsarscov2 AT luismartinezsobrido immunogenicityandprotectiveefficacyofanintranasalliveattenuatedvaccineagainstsarscov2 AT muhammadmunir immunogenicityandprotectiveefficacyofanintranasalliveattenuatedvaccineagainstsarscov2 |